.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Federal Trade Commission
Moodys
Cantor Fitzgerald
Healthtrust
Johnson and Johnson
Julphar
Express Scripts
Cipla

Generated: September 24, 2017

DrugPatentWatch Database Preview

COLCRYS Drug Profile

« Back to Dashboard

Which patents cover Colcrys, and when can generic versions of Colcrys launch?

Colcrys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in COLCRYS is colchicine. There are fifteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the colchicine profile page.

Summary for Tradename: COLCRYS

Patents:17
Applicants:1
NDAs:1
Suppliers / Packagers: see list9
Bulk Api Vendors: see list59
Clinical Trials: see list16
Patent Applications: see list8,481
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:COLCRYS at DailyMed

Pharmacology for Tradename: COLCRYS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for COLCRYS

Drugname Dosage Strength RLD Submissiondate
colchicineTablets0.6 mgColcrys12/23/2011

Non-Orange Book Patents for Tradename: COLCRYS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,541Methods for concomitant administration of colchicine and a second active agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Chubb
McKesson
Farmers Insurance
Mallinckrodt
Cerilliant
AstraZeneca
Citi
Accenture
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot